TVRD Stock Forecast: Tvardi Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.00
+5.61% on the day

The median 12-month analyst price target for Tvardi Therapeutics, Inc. is $9. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 30 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$13.2M
Ticker Nerd rank
30/ 100
Median analyst target
$9.00
Analysts covering
9
Revenue$0.0
Operating income−$6.6M
Net income−$6.5M
Free cash flow−$9.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.3%
1M
+0.7%
YTD
−76.8%
1Y
−73.8%
From 52W high
−80.0%
From 52W low
+26.0%
$0.79
$5.00
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Tvardi Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
30/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
55
Issuance
54
Accruals
44
Growth
33
Volatility
29
Quality
28
Momentum
27
Value
18

Revisions (55): Analysts have, on balance, been raising their forecasts.

Value (18): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TVRD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TVRD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26TVRDHigh $14.00Median $9.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
7
Buy
1
Hold
1
Sell
$3.00
Low
$9.00
Median
$14.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Nov 2026HC Wainwright & Co.ReiteratesBuy$9.00
18 Nov 2026OppenheimerMaintainsOutperform$10 → $9.00
20 Oct 2026Chardan CapitalInitiatesBuy$8.00
8 Sept 2026LUCID CAPITAL MARKETSAssumesBuy$14
30 July 2026BTIGMaintainsBuy$15 → $5.00
8 July 2026Raymond JamesUpgradeOutperform$10
7 July 2026BTIGReiteratesBuy$15
8 June 2026HC Wainwright & Co.InitiatesBuy—
20 Apr 2026BarclaysDowngradeUnderweight—
1 Apr 2026BarclaysMaintainsEqual-Weight—
1 Apr 2026BTIGReiteratesBuy—
1 Apr 2026Piper SandlerMaintainsNeutral—
14 Oct 2025Raymond JamesDowngradeMarket Perform—
13 Oct 2025BarclaysInitiatesOverweight—
13 Oct 2025BTIGMaintainsBuy—
14 July 2025Raymond JamesInitiatesOutperform—
11 July 2025Cantor FitzgeraldInitiatesOverweight—
12 June 2025Piper SandlerInitiatesOverweight—
21 May 2025OppenheimerInitiatesOutperform—
28 Apr 2025Jones TradingInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TVRD.

Market Radar

This page is one stock. Monday covers all of them.

TVRD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TVRD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Tvardi Therapeutics, Inc. returned −73.8% against +6.9% for the S&P 500, dividends included.

TVRD vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26TVRDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TVRD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.4×

Cheaper than 88% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−126.2%

Higher than 11% of US stocks

Return on assets
−55.5%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tvardi Therapeutics, Inc. has a market value of $13.2M and an enterprise value of $120K.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$26.1M.

  • Diluted earnings per share, trailing twelve months: −$2.79.

  • Free cash flow in the twelve months to 30 June 2026: −$25.0M.

  • Shares outstanding: 9.4M.

  • Tvardi Therapeutics, Inc. employs 12 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

TVRD and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TVRDTvardi Therapeutics, Inc.$13.2M30
ABOSAcumen Pharmaceuticals, Inc.$13.5M42
ESLAEstrella Immunopharma, Inc.$13.5M26
PLURPluri, Inc.$13.5M17
NCELNewCelX Ltd.$13.6M4
BOLTBolt Biotherapeutics, Inc.$12.8M78
ACTUActuate Therapeutics, Inc.$13.6M39

Take a look at TVRD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Tvardi Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TVRD

What is the TVRD stock price forecast for 2026-2027?

The median 12-month analyst price target for Tvardi Therapeutics, Inc. is $9, with estimates ranging from $3 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TVRD stock a buy right now?

Of the 9 analysts covering Tvardi Therapeutics, Inc., 7 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Tvardi Therapeutics, Inc. 30 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TVRD?

As at 21 Nov 2026, Tvardi Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (55 of 100).

Will TVRD stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts is $9, and Ticker Nerd's factor model ranks Tvardi Therapeutics, Inc. 30 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TVRD stock forecast for 2030?

No analyst covering Tvardi Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TVRD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $14 over the next 12 months.

How has TVRD stock performed over the past year?

Tvardi Therapeutics, Inc. returned -73.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tvardi Therapeutics, Inc. do?

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule therapies that target STAT3, a signaling pathway associated with inflammatory and proliferative diseases. The company’s current pipeline includes TTI-101, which is being studied for fibrosis-driven diseases such as idiopathic pulmonary fibrosis and hepatocellular carcinoma, and TTI-109, a next-generation oral STAT3 inhibitor in early clinical development.

Company

About Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule therapies that target STAT3, a signaling pathway associated with inflammatory and proliferative diseases. The company’s current pipeline includes TTI-101, which is being studied for fibrosis-driven diseases such as idiopathic pulmonary fibrosis and hepatocellular carcinoma, and TTI-109, a next-generation oral STAT3 inhibitor in early clinical development. Tvardi Therapeutics concentrates on conditions with significant unmet medical need, positioning its research around disease areas where targeted therapies may address complex biological pathways. Based in Sugar Land, Texas, Tvardi Therapeutics serves the biotechnology market through a pipeline centered on precision, mechanism-based drug development.

CEO Dr. Imran Alibhai Ph.D. · 12 employees · United States · https://tvarditherapeutics.com